<DOC>
	<DOCNO>NCT01535157</DOCNO>
	<brief_summary>The purpose study determine effectiveness fenretinide ( 4-HPR/LXS ) plus ketoconazole treatment recurrent ovarian cancer primary peritoneal carcinoma . In addition , researcher would like determine drug effective together fenretinide ( 4-HPR/LXS ) effective alone .</brief_summary>
	<brief_title>Fenretinide/LXS Oral Powder Plus Ketoconazole Recurrent Ovarian Cancer</brief_title>
	<detailed_description>In study , initial Phase I component six patient conduct monitor potential toxicity wil initial adult experience fenretinide ( 4-HPR ) give together ketoconazole</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Fenretinide</mesh_term>
	<criteria>Recurrent epithelial ovarian cancer primary peritoneal carcinoma platinum sensitive platinum resistant SWOG Performance Status 02 Previously receive platinum paclitaxel contain regimen Projected Life Expectancy least 3 month Adequate bone marrow function Adequate organ function Must receive least 1 prior salvage regimen recurrent ovarian cancer Recovery acute toxicity surgery , radiation chemotherapy At least 3 week last therapy Prior fenretinide oral capsule use allow . If prior IV fenretinide use , must contact study chair eligibility Second malignancy within last 5 year Use concomitant antioxidant , vitamin C E Untreated symptomatic brain metastasis History hypertriglyceride level &gt; 200 mg/dl ; triglyceride level &lt; 200 receive treatment okay . Use certain medication prohibit contact study coordinator information</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chemotherapy</keyword>
</DOC>